A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors.
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Erlotinib; Pertuzumab
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 11 Jul 2011 Planned end date changed from 1 Oct 2011 to 1 May 2010 as reported by ClinicalTrials.gov record.
- 07 Jul 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 12 Apr 2011 Planned end date changed from Feb 2011 to Oct 2011 as reported by ClinicalTrials.gov.